Unlock instant, AI-driven research and patent intelligence for your innovation.

A biomarker syt12 of osteosarcoma and its application

A 1. SYT12, osteosarcoma technology, applied in the field of osteosarcoma biomarkers, can solve the problem of less molecular targets

Active Publication Date: 2020-11-27
GUAN BOJIAN BIOTECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Molecular targeted therapy has high specificity, reduces the toxic and side effects on normal tissue cells around the tumor, and has a very good application prospect. Although the search for molecular targets of osteosarcoma has received more and more attention, there are still relatively few molecular targets reported , cannot meet the clinical needs, so it is of great significance to find new specific and efficient molecular targets for osteosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A biomarker syt12 of osteosarcoma and its application
  • A biomarker syt12 of osteosarcoma and its application
  • A biomarker syt12 of osteosarcoma and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1 Screening of Gene Markers Related to Osteosarcoma

[0071] 1. Sample collection

[0072] Six cases of osteosarcoma tissue and paracancerous tissue samples were collected, and the informed consent of the tissue samples was obtained from the patients, and all of them were approved by the organizational ethics committee.

[0073] 2. Preparation of RNA samples

[0074] Take out the tissue samples frozen in liquid nitrogen, put the tissue samples into a pre-cooled mortar for grinding, and extract and isolate RNA according to the instructions in the kit. details as follows:

[0075] 1) Add Trizol and place at room temperature for 5 minutes;

[0076] 2) Add 0.2ml of chloroform, vibrate the centrifuge tube vigorously, mix well, and place it at room temperature for 5-10min;

[0077] 3) Centrifuge at 12000rpm for 15min, transfer the upper aqueous phase to another new centrifuge tube (be careful not to absorb the protein material between the two aqueous phases), add ...

Embodiment 2

[0089] Example 2 QPCR sequencing to verify the differential expression of the SYT12 gene

[0090] 1. Large-sample QPCR verification of differential expression of SYT12 gene. According to the sample collection method in Example 1, 50 cases of paracancerous tissues and 50 osteosarcoma tissues of osteosarcoma patients were selected.

[0091] 2. RNA extraction The specific steps are as described in Example 1.

[0092] 3. Reverse transcription

[0093] mRNA reverse transcription was performed using the FastQuant cDNA First Strand Synthesis Kit (Product No.: KR106). Specific steps are as follows:

[0094] Prepare a 20μl reaction system under ice bath conditions: 4×FQ-RT Super Mix 5μl, RNA 1μg, RnaseFree ddH 2 Make up to 20 μl with O, incubate at 42°C for 15 minutes, incubate at 95°C for 3 minutes, and place on ice.

[0095] 4. QPCR amplification

[0096] (1) Primer design

[0097] The primers for QPCR amplification were designed according to the sequences of the SYT12 gene an...

Embodiment 3

[0103] Example 3 Differential expression of SYT12 protein detected by protein immunoblotting

[0104] 1. Extraction of total tissue protein

[0105] Cut the tissue into pieces with scissors, put it into a glass homogenizer, add RIPA lysate, crush the tissue with the glass homogenizer until it is fully lysed, suck the lysed liquid into the EP tube, centrifuge at 14000rpm at 4°C for 5min, Collect the supernatant.

[0106] 2. Determination of total protein concentration

[0107] The protein concentration was determined according to the instructions of the BCA protein concentration determination kit.

[0108] 3. SDS-PAGE electrophoresis

[0109] Prepare 8% separating gel and 5% stacking gel according to the instructions of the SDS-PAGE gel preparation kit and perform electrophoresis.

[0110] 4. Western blot detection

[0111] 1) Electrotransfer

[0112] Put the PVDF membrane into methanol solution to activate for 5 minutes, and put it into the transfer buffer to equilibrate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses osteosarcoma biological marker SYT12, and applications thereof. It is confirmed that up-regulated expression of SYT12 in patients with osteosarcoma is induced, interference ofthe expression of SYT12 is capable of inhibiting cell propagation and invasion, so that it is concluded that SYT12 can be adopted in clinical diagnosis and treatment of osteosarcoma. The invention also provides a method used for screening substances with potential treatment effects on osteosarcoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a biomarker SYT12 of osteosarcoma and its application. Background technique [0002] Osteosarcoma, also known as osteogenic sarcoma, is a malignant primary bone tumor that commonly occurs in childhood and adolescence. The incidence of osteosarcoma in malignant tumors accounts for about 0.4%. It originates from mesenchymal tissue and is characterized by the ability to produce tumor-like bone, immature bone or even no osteoid matrix. The typical site of the disease is the long tubular bones of the extremities, and it is more likely to occur in the proximal end of the bone, the distal femur, and the proximal tibia, and occasionally in the spine and bones. The rate of hematogenous metastasis is high, and the most common site is the lung. The prognosis of most patients with osteosarcoma is very poor, and lung metastasis is the most common cause of death. Currently, the clinical treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886A61K31/7105A61K48/00A61P35/00C12N15/113G01N33/574
CPCA61K31/7105A61K48/00C12Q1/6886C12Q2600/178G01N33/574
Inventor 杨承刚常鹏孙耀兰
Owner GUAN BOJIAN BIOTECH CO LTD